SIMO, Acer, and MediaTek Expand Availability of Acer TravelMate P4 14 to Eight New Markets
27.3.2025 12:00:00 CET | Business Wire | Press Release
SIMO, a leader in innovative connectivity solutions, in collaboration with Acer and MediaTek, proudly announces the expansion of the Acer TravelMate P4 14 (TMP414-53-G2), an Always Connected PC (ACPC) with vSIM technology built-in, into eight new international markets. As part of its global expansion, the Acer TravelMate P4 14 is now available in Spain, France, Germany, the United Kingdom, Poland, Italy, Ireland, and Switzerland, with plans to further expand into additional regions later this year.
Initially launched in select regions last year, the TravelMate P4 14 has gained traction among international travelers, remote workers, and mobile professionals who require seamless, global connectivity without reliance on physical SIM cards or public Wi-Fi.
“Expanding into these new markets is a direct response to the needs of professionals who require secure, reliable connectivity wherever they go,” said Jing Liu, CEO of SIMO. “We're proud to expand availability to these eight new European markets alongside Acer and MediaTek.”
Reliable Connectivity For Professionals On The Move
The Acer TravelMate P4 14 (TMP414-53-G2) meets the demands of today’s highly mobile users, providing seamless global connectivity through the SIMO 365 service. With SIMO 365, customers can enjoy free data for a year. The first 1,000 units sold will include an exclusive bonus of 2GB of free data for the first year. After the initial 1,000 units, customers will still benefit from 30 minutes of free daily 4G internet access for one year. Be among the first 1,000 to unlock even more data! This feature allows users to quickly check emails, access important documents, or connect with colleagues through videoconferencing platforms such as Microsoft Teams, Zoom, or Google Meet without worrying about data limitations.
“Professionals need a laptop that provides seamless connectivity regardless of their location, and the Acer TravelMate P4 14 delivers just that,” said James Lin, GM, Notebooks, Acer. “By expanding its availability, we’re giving more users the flexibility to stay productive and connected at all times.”
Key Features of the TravelMate P4 14
- Built-in LTE connectivity: Users can enjoy lightning-fast internet access, eliminating the need for potentially unreliable or unavailable public Wi-Fi.
- Multi-carrier vSIM Technology: TravelMate P4 14 can automatically select the best local network available across more than 300 mobile carriers in over 140 countries.
- High-performance Specs: Up to 64GB DDR5 RAM, two Thunderbolt 4 ports, and long battery life for uninterrupted productivity.
- Ultra-portable design: Lightweight and sleek for effortless mobility.
- Flexible Data Plans:Includes free data for a year, with 2GB for the first 1,000 units and 30 minutes of free daily 4G access globally. Flexible data plans available beyond the free 30 minutes.
“The TravelMate P4 14, powered by MediaTek’s advanced processors, delivers high-speed LTE and global connectivity,” said CK Wang, VP and GM of IOT Business Unit at MediaTek. “Our expansion with Acer and SIMO enables a mobile experience that meets the needs of today’s always-connected professionals.”
Pricing and Availability
The Acer TravelMate P4 14 is now available in:
- Spain, France, Italy: €1,399.00
- Germany: €1,399.00
- United Kingdom: £1,299.00
- Ireland: €1,499.00
- Switzerland: 1,299 CHF
- Poland: 5,999.00 PLN
Acer is offering a limited-time promotion on the TravelMate P4 14 through the end of March. Visit each country’s product page for details on available discounts.
For more information, visit www.simo.co/travelmate
About SIMO
SIMO is a leading provider of connectivity solutions, dedicated to delivering seamless, reliable, and innovative internet services through proprietary virtual SIM (vSIM) technology. With a commitment to keeping people connected, SIMO’s products are designed for consumers, small businesses, and enterprises worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327701331/en/
Contacts
Media Inquiries:
Jadin Roberson
Jadin@pitchpublicrelations.com
Pitch Public Relations
SIMO Press Office [pr@simo.co]
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom